Intellia Therapeutics, Inc.
NTLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 59.6% | -30.4% | 57.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 82.2% | 75.3% | 85.5% | 79.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $0 |
| Operating Income | -$1 | -$1 | -$0 | -$0 |
| % Margin | -923.1% | -1,420.5% | -879% | -810.4% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | -896.8% | -1,326.5% | -909.8% | -810.5% |
| EPS | -5.25 | -5.42 | -6.16 | -3.78 |
| % Growth | 3.1% | 12% | -63% | – |
| EPS Diluted | -5.25 | -5.42 | -6.16 | -3.78 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$0 | -$0 |
| % Margin | -905.3% | -1,395.8% | -864.5% | -789.5% |